Amgen (AMGN) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Amgen (AMGN) has outperformed Pfizer (PFE) over the past year, gaining 39.8% versus a gain of 6.6%. Over five years, AMGN leads with a +98.5% price change compared with -32.5% for PFE. Amgen is the larger company by market cap ($223.32 billion vs $159.59 billion), about 1.4 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.7x vs 16.9x for Amgen). Pfizer offers the higher dividend yield (6.14% vs 2.37%). Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 12.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | PFE |
|---|---|---|
| Share price | $413.08 | $28.00 |
| Market cap | $223.32B | $159.59B |
| 1-day change | +2.60% | +1.82% |
| YTD return | +26.20% | +12.45% |
| 1-year return | +39.77% | +6.59% |
| 5-year return | +98.50% | -32.51% |
| P/E ratio (TTM) | 25.66 | 36.84 |
| Forward P/E | 16.88 | 9.67 |
| EPS (TTM) | $16.10 | $0.76 |
| Dividend yield | 2.37% | 6.14% |
| Annual dividend | $9.80 | $1.72 |
| Revenue (latest FY) | $36.75B | $62.58B |
| Revenue growth (YoY) | +9.95% | -1.65% |
| Net income (latest FY) | $7.71B | $7.77B |
| Gross margin | 67.25% | 74.33% |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | 12.42% |
| 52-week high | $447.03 | $29.21 |
| 52-week low | $288.00 | $23.62 |
| Distance from 52-week high | -7.59% | -4.14% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -5.23% | +3.25% |
| Average volume | 2.72M | 36.05M |
| Shares outstanding | 540.63M | 5.70B |
| Employees | 31,500 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMGN has outperformed PFE by 33.2 percentage points over the past year.
- Pfizer trades at a higher earnings multiple (36.8x vs 25.7x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (6.14% vs 2.37%).
- Amgen is more profitable, keeping 21.0 cents of every revenue dollar as net income versus 12.4 cents for Pfizer.
- Amgen grew revenue faster in its latest fiscal year (+9.95% vs -1.65%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
AMGN vs PFE FAQ
Which is bigger, Amgen or Pfizer?
Amgen (AMGN) is larger, with a market capitalization of $223.32B compared with $159.59B for Pfizer (PFE).
Which stock has performed better over the past year, AMGN or PFE?
AMGN returned +39.77% over the past 12 months, compared with +6.59% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or PFE?
AMGN has the lower trailing P/E at 25.7, versus 36.8 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Pfizer?
Pfizer has the higher yield at 6.14%, compared with 2.37% for Amgen.
Are Amgen and Pfizer in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Amgen and Biotechnology: Pharmaceutical Preparations for Pfizer.